Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
8.96
-0.27 (-2.93%)
Mar 31, 2025, 3:11 PM EDT - Market open
Theravance Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 37.8 | 39.55 | 298.17 | 89.96 | 81.47 | Upgrade
|
| Short-Term Investments | 50.55 | 62.88 | 29.31 | 83.51 | 211.47 | Upgrade
|
| Cash & Short-Term Investments | 88.35 | 102.43 | 327.48 | 173.47 | 292.94 | Upgrade
|
| Cash Growth | -13.74% | -68.72% | 88.79% | -40.78% | 4.31% | Upgrade
|
| Accounts Receivable | 18.44 | 17.47 | 16.79 | 14.07 | 15.87 | Upgrade
|
| Other Receivables | 50 | - | - | - | 53.8 | Upgrade
|
| Receivables | 68.44 | 17.47 | 16.79 | 14.07 | 69.67 | Upgrade
|
| Prepaid Expenses | 4.28 | 13.64 | 9.2 | 18.81 | 30.73 | Upgrade
|
| Other Current Assets | - | - | - | 43.53 | - | Upgrade
|
| Total Current Assets | 161.07 | 133.54 | 353.46 | 249.87 | 393.34 | Upgrade
|
| Property, Plant & Equipment | 35.77 | 45.36 | 52 | 53.35 | 59.68 | Upgrade
|
| Long-Term Investments | - | - | - | - | 12.75 | Upgrade
|
| Other Long-Term Assets | 157.32 | 203.1 | 201.94 | 71.6 | 3.28 | Upgrade
|
| Total Assets | 354.16 | 382 | 607.4 | 374.82 | 469.06 | Upgrade
|
| Accounts Payable | 2.24 | 1.52 | 1.55 | 3.1 | 6.78 | Upgrade
|
| Accrued Expenses | 13.28 | 12.83 | 20.41 | 37.95 | 76.07 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 16.94 | 19.33 | Upgrade
|
| Current Portion of Leases | 10.71 | 3.92 | 6.75 | 0.5 | 9.87 | Upgrade
|
| Current Income Taxes Payable | 5.85 | - | - | - | - | Upgrade
|
| Current Unearned Revenue | - | - | - | 0.1 | 11.52 | Upgrade
|
| Other Current Liabilities | - | 6.49 | - | - | - | Upgrade
|
| Total Current Liabilities | 32.09 | 24.77 | 28.72 | 58.59 | 123.57 | Upgrade
|
| Long-Term Debt | - | - | - | 599.39 | 599.84 | Upgrade
|
| Long-Term Leases | 39.11 | 45.24 | 45.41 | 52.68 | 47.22 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 0.19 | 0.31 | 0.35 | Upgrade
|
| Other Long-Term Liabilities | 107.42 | 99 | 91.29 | 2.42 | 1.83 | Upgrade
|
| Total Liabilities | 178.62 | 169 | 165.6 | 713.39 | 772.81 | Upgrade
|
| Common Stock | - | - | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,141 | 1,122 | 1,296 | 1,387 | 1,223 | Upgrade
|
| Retained Earnings | -965.52 | -909.1 | -853.91 | -1,726 | -1,527 | Upgrade
|
| Comprehensive Income & Other | 0.01 | -0.07 | -0.02 | - | 0.05 | Upgrade
|
| Shareholders' Equity | 175.55 | 213 | 441.8 | -338.57 | -303.75 | Upgrade
|
| Total Liabilities & Equity | 354.16 | 382 | 607.4 | 374.82 | 469.06 | Upgrade
|
| Total Debt | 49.82 | 49.16 | 52.16 | 669.52 | 676.26 | Upgrade
|
| Net Cash (Debt) | 38.53 | 53.27 | 275.32 | -496.05 | -383.32 | Upgrade
|
| Net Cash Growth | -27.67% | -80.65% | - | - | - | Upgrade
|
| Net Cash Per Share | 0.79 | 0.96 | 3.74 | -7.14 | -6.15 | Upgrade
|
| Filing Date Shares Outstanding | 49.47 | 48.16 | 62.86 | 74.7 | 64.33 | Upgrade
|
| Total Common Shares Outstanding | 49.47 | 48.09 | 65.23 | 74.44 | 64.33 | Upgrade
|
| Working Capital | 128.98 | 108.77 | 324.75 | 191.28 | 269.77 | Upgrade
|
| Book Value Per Share | 3.55 | 4.43 | 6.77 | -4.55 | -4.72 | Upgrade
|
| Tangible Book Value | 175.55 | 213 | 441.8 | -338.57 | -303.75 | Upgrade
|
| Tangible Book Value Per Share | 3.55 | 4.43 | 6.77 | -4.55 | -4.72 | Upgrade
|
| Machinery | 3.74 | 3.68 | 19.04 | 26.03 | 35.88 | Upgrade
|
| Leasehold Improvements | 25.32 | 26.21 | 24.58 | 24.05 | 24.28 | Upgrade
|
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.